R Squared’s Acrivon Therapeutics ACRV Stock Holding History

R Squared’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20	Closed	-$120	–	306
2024 Q4	$120	Buy	+20	New	+$145	﹤0.01%	1567

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

R Squared's ACRV Position: Q1 2025 in Review

R Squared sold out of Acrivon Therapeutics (ACRV) in Q1 2025, closing a stake of 20 shares — an estimated $120 sold.

R Squared first reported a position in ACRV in Q4 2024 and held it in 1 quarter. The position peaked at $120 in Q4 2024. 63 funds tracked by Wall St. Rank hold ACRV as of Q1 2025.

R Squared reported no remaining Acrivon Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 20 Acrivon Therapeutics shares in Q1 2025, an estimated $120.
R Squared first reported a position in Acrivon Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Acrivon Therapeutics position peaked at $120 in Q4 2024.
63 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.